Please read these important legal notices and disclosures
None of the information displayed on or downloadable from https://www.precize.in represents an offer to buy or sell or a solicitation of an offer to buy or sell any security, nor does it constitute an offer to provide investment advice or service. Registered representatives of precize do not (1) Advise any member on the merits or advisability of a particular investment or transaction, or (2) Assist in the determination of fair value of any security or investment, or (3) Provide legal, tax, or transactional advisory services.
Arch Pharmalabs Unlisted Share Price Today
52-week range ₹82 to ₹126.
ISIN INE182F01017.
About Company Arch Pharmalabs is a specialty pharmaceutical company in India , engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and contract development & manufacturing services (CRAMS/CDMO) for global pharmaceutical companies. The company serves both innovator and generic players across domestic and regulated international markets , with a strong focus on complex chemistry and high-quality manufacturing. Arch operates a dual business model combinin…
Arch Pharmalabs
Arch Pharmalabs is a specialty pharmaceutical company in India, engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and contract development & manufacturing services (CRAMS/CDMO) for global pharmaceutical companies. The company serves both innovator and generic players across domestic and regulated international markets, with a strong focus on complex chemistry and high-quality manufacturing. Arch operates a dual business model combining products and services, where its API and intermediates segment provides stable revenues, while the CRAMS/CDMO segment focuses on high-margin custom synthesis, process development, and commercial manufacturing for global clients. The company is increasingly moving up the value chain by targeting innovator-led projects, long-term contracts, and complex molecule manufacturing, strengthening its positioning as a strategic outsourcing partner.
The company has built strong capabilities in process chemistry, analytical development, and scale-up manufacturing, supported by multiple cGMP-compliant manufacturing facilities and global regulatory approvals (USFDA, EU, WHO, etc.), enabling it to cater to regulated markets such as the US, Europe, and Japan. Its business is closely linked to global outsourcing trends, drug development pipelines, and demand for complex APIs, making R&D capabilities and regulatory compliance critical to long-term growth.
Headquartered in Mumbai, Arch Pharmalabs operates several manufacturing facilities across the country and serves a diversified global customer base, ranging from large pharmaceutical innovators to specialty and generic companies, positioning itself as a key player in the CRAMS/CDMO and specialty pharma ecosystem.
Mr. Ajit Kamath is the Chairman & Managing Director of Arch Pharmalabs and founder, with over 20+ years of experience in the pharmaceutical industry. He has been instrumental in driving strategy, acquisitions, and global business development, building Arch into a leading CRAMS/API player.
